{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:00:31Z","timestamp":1793948431903,"version":"4.8.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Sydney Medical Foundation"},{"name":"National Health and Medical Research Council of Australia","award":["APP1053206"],"award-info":[{"award-number":["APP1053206"]}]},{"name":"Cancer Institute","award":["2021\/ATRG2028"],"award-info":[{"award-number":["2021\/ATRG2028"]}]},{"name":"Medica Sur Clinic & Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s12072-023-10620-y","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T12:01:57Z","timestamp":1703160117000},"page":"168-178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Breaking new ground: MASLD vs. MAFLD\u2014which holds the key for risk stratification?"],"prefix":"10.1007","volume":"18","author":[{"given":"Mariana Michelle","family":"Ram\u00edrez-Mej\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Jim\u00e9nez-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Eslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5257-8048","authenticated-orcid":false,"given":"Nahum","family":"M\u00e9ndez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"issue":"6","key":"10620_CR1","doi-asserted-by":"publisher","first-page":"101138","DOI":"10.1016\/j.aohep.2023.101138","volume":"28","author":"MM Ram\u00edrez-Mej\u00eda","year":"2023","unstructured":"Ram\u00edrez-Mej\u00eda MM, Qi X, Abenavoli L, Romero-G\u00f3mez M, Eslam M, M\u00e9ndez-S\u00e1nchez N. Metabolic dysfunction: the silenced connection with fatty liver disease. Ann Hepatol. 2023;28(6):101138. https:\/\/doi.org\/10.1016\/j.aohep.2023.101138. (Epub 20230717; PubMed PMID: 37468095)","journal-title":"Ann Hepatol"},{"issue":"9","key":"10620_CR2","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1210\/clinem\/dgac321","volume":"107","author":"KE Chan","year":"2022","unstructured":"Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107(9):2691\u20132700. https:\/\/doi.org\/10.1210\/clinem\/dgac321. (PubMed PMID: 35587339)","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10620_CR3","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/s2468-1253(21)00183-7","volume":"6","author":"M Eslam","year":"2021","unstructured":"Eslam M, Alkhouri N, Vajro P, Baumann U, Weiss R, Socha P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol. 2021;6(10):864\u2013873. https:\/\/doi.org\/10.1016\/s2468-1253(21)00183-7. (Epub 20210806 PubMed PMID: 34364544)","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"1","key":"10620_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u2013209. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039. (Epub 20200408 PubMed PMID: 32278004)","journal-title":"J Hepatol"},{"issue":"3","key":"10620_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.cgh.2021.11.038","volume":"21","author":"GEH Lim","year":"2023","unstructured":"Lim GEH, Tang A, Ng CH, Chin YH, Lim WH, Tan DJH, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2023;21(3):619\u201329.e7. https:\/\/doi.org\/10.1016\/j.cgh.2021.11.038. (Epub 20211204 PubMed PMID: 34871813)","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10620_CR6","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1111\/liv.14675","volume":"40","author":"S Yamamura","year":"2020","unstructured":"Yamamura S, Eslam M, Kawaguchi T, Tsutsumi T, Nakano D, Yoshinaga S, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020;40(12):3018\u20133030. https:\/\/doi.org\/10.1111\/liv.14675. (PubMed PMID: 32997882)","journal-title":"Liver Int"},{"issue":"5","key":"10620_CR7","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/s2468-1253(22)00062-0","volume":"7","author":"N M\u00e9ndez-S\u00e1nchez","year":"2022","unstructured":"M\u00e9ndez-S\u00e1nchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7(5):388\u2013390. https:\/\/doi.org\/10.1016\/s2468-1253(22)00062-0. (Epub 20220303 PubMed PMID: 35248211)","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"10620_CR8","doi-asserted-by":"publisher","first-page":"e933860","DOI":"10.12659\/msm.933860","volume":"27","author":"N M\u00e9ndez-S\u00e1nchez","year":"2021","unstructured":"M\u00e9ndez-S\u00e1nchez N, D\u00edaz-Orozco LE. Editorial: International consensus recommendations to replace the terminology of non-alcoholic fatty liver disease (NAFLD) with metabolic-associated fatty liver disease (MAFLD). Med Sci Monit. 2021;27:e933860. https:\/\/doi.org\/10.12659\/msm.933860. (Epub 20210712, PubMed PMID: 34248137; PubMed Central PMCID: PMC8284081)","journal-title":"Med Sci Monit"},{"issue":"2","key":"10620_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/liv.14739","volume":"41","author":"Y Fouad","year":"2021","unstructured":"Fouad Y, Elwakil R, Elsahhar M, Said E, Bazeed S, Ali Gomaa A, et al. The NAFLD-MAFLD debate: eminence vs evidence. Liver Int. 2021;41(2):255\u2013260. https:\/\/doi.org\/10.1111\/liv.14739. (Epub 20201202 PubMed PMID: 33220154)","journal-title":"Liver Int"},{"issue":"3","key":"10620_CR10","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/hep.31420","volume":"73","author":"ZM Younossi","year":"2021","unstructured":"Younossi ZM, Rinella ME, Sanyal AJ, Harrison SA, Brunt EM, Goodman Z, et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology. 2021;73(3):1194\u20131198. https:\/\/doi.org\/10.1002\/hep.31420. (Epub 20210206 PubMed PMID: 32544255)","journal-title":"Hepatology"},{"key":"10620_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003. (Epub 20230620. PubMed PMID: 37364790)","journal-title":"J Hepatol"},{"key":"10620_CR12","doi-asserted-by":"publisher","first-page":"204201882211455","DOI":"10.1177\/20420188221145549","volume":"14","author":"RM Pipitone","year":"2023","unstructured":"Pipitone RM, Ciccioli C, Infantino G, La Mantia C, Parisi S, Tulone A, et al. MAFLD: a multisystem disease. Ther Adv Endocrinol Metab. 2023;14:20420188221145548. https:\/\/doi.org\/10.1177\/20420188221145549. (Epub 20230128. PubMed PMID: 36726391; PubMed Central PMCID: PMC9885036)","journal-title":"Ther Adv Endocrinol Metab."},{"key":"10620_CR13","doi-asserted-by":"publisher","first-page":"934225","DOI":"10.3389\/fendo.2022.934225","volume":"13","author":"W Wen","year":"2022","unstructured":"Wen W, Li H, Wang C, Chen C, Tang J, Zhou M, et al. Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: a meta-analysis. Front Endocrinol (Lausanne). 2022;13:934225. https:\/\/doi.org\/10.3389\/fendo.2022.934225. (Epub 20220916. PubMed PMID: 36187109; PubMed Central PMCID: PMC9523252)","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"11","key":"10620_CR14","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1111\/liv.14623","volume":"40","author":"G Targher","year":"2020","unstructured":"Targher G. Concordance between MAFLD and NAFLD diagnostic criteria in \u2018real-world\u2019 data. Liver Int. 2020;40(11):2879\u20132880. https:\/\/doi.org\/10.1111\/liv.14623. (PubMed PMID: 32738082)","journal-title":"Liver Int"},{"key":"10620_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111629","author":"J Guti\u00e9rrez-Cuevas","year":"2021","unstructured":"Guti\u00e9rrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with cardiovascular diseases. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222111629. (Epub 20211027. PubMed PMID: 34769060; PubMed Central PMCID: PMC8583943)","journal-title":"Int J Mol Sci"},{"key":"10620_CR16","doi-asserted-by":"publisher","first-page":"154766","DOI":"10.1016\/j.metabol.2021.154766","volume":"119","author":"MA Hill","year":"2021","unstructured":"Hill MA, Yang Y, Zhang L, Sun Z, Jia G, Parrish AR, et al. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism. 2021;119:154766. https:\/\/doi.org\/10.1016\/j.metabol.2021.154766. (Epub 20210322 PubMed PMID: 33766485)","journal-title":"Metabolism"},{"issue":"2","key":"10620_CR17","doi-asserted-by":"publisher","first-page":"101215","DOI":"10.1016\/j.diabet.2020.101215","volume":"47","author":"G Targher","year":"2021","unstructured":"Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes Metab. 2021;47(2):101215. https:\/\/doi.org\/10.1016\/j.diabet.2020.101215. (Epub 20201206. PubMed PMID: 33296704)","journal-title":"Diabetes Metab"},{"issue":"7","key":"10620_CR18","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.312. (Epub 20200208 PubMed PMID: 32044314)","journal-title":"Gastroenterology"},{"issue":"9","key":"10620_CR19","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/liv.14548","volume":"40","author":"S Lin","year":"2020","unstructured":"Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020;40(9):2082\u20132089. https:\/\/doi.org\/10.1111\/liv.14548. (Epub 20200726 PubMed PMID: 32478487)","journal-title":"Liver Int"},{"issue":"10","key":"10620_CR20","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.cgh.2021.05.029","volume":"19","author":"VH Nguyen","year":"2021","unstructured":"Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential clinical characteristics and mortality outcomes in persons with NAFLD and\/or MAFLD. Clin Gastroenterol Hepatol. 2021;19(10):2172\u201381.e6. https:\/\/doi.org\/10.1016\/j.cgh.2021.05.029. (Epub 20210523 PubMed PMID: 34033923)","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10620_CR21","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1016\/j.cgh.2022.09.028","volume":"21","author":"KE Chan","year":"2023","unstructured":"Chan KE, Ng CH, Fu CE, Quek J, Kong G, Goh YJ, et al. The spectrum and impact of metabolic dysfunction in MAFLD: a longitudinal cohort analysis of 32,683 overweight and obese individuals. Clin Gastroenterol Hepatol. 2023;21(10):2560\u20139.e15. https:\/\/doi.org\/10.1016\/j.cgh.2022.09.028. (Epub 20221003 PubMed PMID: 36202348)","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10620_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10568-z","author":"K Vaz","year":"2023","unstructured":"Vaz K, Clayton-Chubb D, Majeed A, Lubel J, Simmons D, Kemp W, et al. Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes. Hepatol Int. 2023. https:\/\/doi.org\/10.1007\/s12072-023-10568-z. (Epub 20230809. PubMed PMID: 37556065)","journal-title":"Hepatol Int"},{"issue":"5","key":"10620_CR23","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/hepr.13706","volume":"52","author":"T Kawaguchi","year":"2022","unstructured":"Kawaguchi T, Tsutsumi T, Nakano D, Torimura T. MAFLD: Renovation of clinical practice and disease awareness of fatty liver. Hepatol Res. 2022;52(5):422\u2013432. https:\/\/doi.org\/10.1111\/hepr.13706. (Epub 20210917 PubMed PMID: 34472683)","journal-title":"Hepatol Res"},{"issue":"7","key":"10620_CR24","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.tem.2021.04.008","volume":"32","author":"S Lim","year":"2021","unstructured":"Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab. 2021;32(7):500\u2013514. https:\/\/doi.org\/10.1016\/j.tem.2021.04.008. (Epub 20210508 PubMed PMID: 33975804)","journal-title":"Trends Endocrinol Metab"},{"issue":"5","key":"10620_CR25","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/jgh.13264","volume":"31","author":"S Ballestri","year":"2016","unstructured":"Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(5):936\u2013944. https:\/\/doi.org\/10.1111\/jgh.13264. (PubMed PMID: 26667191)","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"10620_CR26","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/dom.14322","volume":"23","author":"B Cariou","year":"2021","unstructured":"Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: a literature review. Diabetes Obes Metab. 2021;23(5):1069\u20131083. https:\/\/doi.org\/10.1111\/dom.14322. (Epub 20210210. PubMed PMID: 33464677; PubMed Central PMCID: PMC8248154)","journal-title":"Diabetes Obes Metab"},{"key":"10620_CR27","doi-asserted-by":"publisher","first-page":"693507","DOI":"10.3389\/fmed.2021.693507","volume":"8","author":"Q Huang","year":"2021","unstructured":"Huang Q, Zou X, Wen X, Zhou X, Ji L. NAFLD or MAFLD: which has closer association with all-cause and cause-specific mortality?-results from NHANES III. Front Med (Lausanne). 2021;8:693507. https:\/\/doi.org\/10.3389\/fmed.2021.693507. (Epub 20210701. PubMed PMID: 34277667; PubMed Central PMCID: PMC8280321)","journal-title":"Front Med (Lausanne)."},{"issue":"1","key":"10620_CR28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1210\/clinem\/dgab641","volume":"107","author":"Y Liang","year":"2022","unstructured":"Liang Y, Chen H, Liu Y, Hou X, Wei L, Bao Y, et al. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China. J Clin Endocrinol Metab. 2022;107(1):88\u201397. https:\/\/doi.org\/10.1210\/clinem\/dgab641. (PubMed PMID: 34508601; PubMed Central PMCID: PMC8684479)","journal-title":"J Clin Endocrinol Metab"},{"key":"10620_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.07.021","author":"SJ Song","year":"2023","unstructured":"Song SJ, Lai JC-T, Wong GL-H, Wong VW-S, Yip TC-F. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2023. https:\/\/doi.org\/10.1016\/j.jhep.2023.07.021","journal-title":"J Hepatol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10620-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-023-10620-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10620-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T04:41:19Z","timestamp":1707540079000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-023-10620-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10620"],"URL":"https:\/\/doi.org\/10.1007\/s12072-023-10620-y","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]},"assertion":[{"value":"23 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of Medica Sur Clinic & Foundation (protocol code 2021-EXT-552 and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}